Abstract
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment.
Kalorama Information' s Congestive Heart Failure, Major World Markets series looks at CHF treatment. Volume I of this series looks at Pharmaceutical Treatments in the following key categories which are used to treat this disease:
- ACEIs/ARBs
- Beta-Blockers
- Diuretics
- Inotropes
- Vasodilators
- Aldosterone Inhibitors
This Kalorama Information report includes current market, market forecasts, product discussion and pipeline analysis are included for each segement of this report. General trends in this important disease category are also included. Relevant companies in the industry are profiled. This report is the result of Dr. Kenneth Krul' s exhaustive analysis and primary research with key executives in the industry.
- Abbott Laboratories
- Actelion Pharmaceuticals US
- Aldagen
- Alexion Pharmaceuticals
- AstraZeneca LP
- Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
- Bristol-Myers Squibb
- CardioVascular Biotherapeutics
- CoGenesys, Inc.
- Encysive Pharmaceuticals
- GlaxoSmithKline (US)
- Inotek Pharmaceuticals
- Mylan Pharmaceuticals
- Novartis Pharmaceutical Corp.
- Pfizer, Inc.
- Roche Pharmaceuticals
- Sanofi-Aventis (US)
- Scios, Inc.
- Vasogen, Inc.
- Zealand Pharma
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Background
- Scope and Methodology
- Size and Growth of Market
- Market Trends
- The Nature of the Industry
- The New Technologies
CHAPTER TWO: INTRODUCTION
- Background
- Pathophysiology
- Types of Heart Failure
- Left Ventricular (LV) Failure
- Right Ventricular (RV) Failure
- Systolic Dysfunction
- Diastolic Dysfunction
- High Output Failure
- Theories of Congestive Heart Failure
- Hemodynamic Response Theory
- Neurohormonal Response Theory
- Renal Response Theory
- Conditions Leading to Congestive Heart Failure
- Myocardial Infarction
- Hypertension
- Cardiomyopathy
- Atrial Fibrillation
- Other Risk Factors
- Diagnosis of Congestive Heart Failure
- Classification of Congestive Heart Failure Patients
- Epidemiology
- United States
- Europe
- Japan
CHAPTER THREE:TREATMENT OF CONGESTIVE HEART FAILURE
- Pharmacological Therapy
- Overview
- Standard Pharmacological Therapy
- ACE Inhibitors and Related Drugs
- Angiotensin II Receptor Inhibitors (ARBs)
- Blockers
- Diuretics
- Positive Inotropic Agents
- Vasodilators
- Aldosterone Blockers
- Limitations of Pharmaceuticals
- Emerging Drugs to Treat Congestive Heart Failure
CHAPTER FOUR: CONGESTIVE HEART FAILURE PATIENT MANAGEMENT
- Guidelines for Management of Chronic Heart Failure
- Strategies to Maintain Quality Patient Care and Con`tain Costs
- Patient Education Programs
- Dedicated Multidisciplinary Congestive Heart Failure Clinics
CHAPTER FIVE: THE MARKET FOR CHF PHARMACEUTICALS
- Market Analysis
- United States
- Europe
- Japan
CHAPTER SIX: COMPANY PROFILES
- Abbott Laboratories
- Actelion Pharmaceuticals US
- Aldagen
- Alexion Pharmaceuticals
- AstraZeneca LP
- Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
- Bristol-Myers Squibb
- CardioVascular Biotherapeutics
- CoGenesys, Inc.
- Encysive Pharmaceuticals
- GlaxoSmithKline (US)
- Inotek Pharmaceuticals
- Mylan Pharmaceuticals
- Novartis Pharmaceutical Corp.
- Pfizer, Inc.
- Roche Pharmaceuticals
- Sanofi-Aventis (US)
- Scios, Inc.
- Vasogen, Inc.
- Zealand Pharma
CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
- Fifth Conclusion
- Sixth Conclusion
- Seventh Conclusion
- Eighth Conclusion
- APPENDIX A: GLOSSARY
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World Healthcare Markets: 2007 - 2017
- Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World Healthcare Markets: 2007 - 2017
- Table 1-1: Estimated Market Sizes for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017 (US$ Billions)
- Figure 1-3: Market Potential Trending and Composition for Congestive Heart Failure Therapeutics in the World' s Major Therapy Markets:2007 - 2017
- Figure 1-4: Composition of the Markets for Congestive Heart Failure Therapeutics by Product Classification: 2007 - 2017 Table 1-3: Examples of Companies Competitive in Congestive Heart Failure Therapeutics
CHAPTER TWO: INTRODUCTION
- Table 2-1: International Cardiovascular Disease (CVD) Statistics
- Table 2-2: United States CHF Statistics: 2004
- Table 2-3: CHF Data Sources
- Table 2-4: Common Contributors to Congestive Heart Failure
- Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World' s Major Healthcare Markets: 2007 - 2017
- Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World Healthcare Markets: 200l - 2017
- Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World Healthcare Markets: 2007 - 2017
- Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 2003
- Table 2-5: Incidence and Prevalence of CHF in the United States: 2007 - 2017
- Figure 2-5: Incidence and Prevalence of CHF in the United States: 2007 - 2017
- Figure 2-6: The Distribution of Congestive Heart Failure In the Five Major European Healthcare Markets: 2007
- Table 2-6: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 - 2017 (Thousands) Figure 2-7: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 - 20017 (Thousands)
- Table 2-7: Incidence and Prevalence of CHF in Japan: 2007 - 2017
- Figure 2-8: Incidence and Prevalence of CHF in Japan: 2007 - 20017
CHAPTER THREE: TREATMENT OF CONGESTIVE HEART FAILURE
- Table 3-1: Therapeutic Strategies for Symptomatic Congestive Heart Failure
- Table 3-2: Pharmacological Response to the Pathophysiology of Cardiac Performance
- Table 3-3: Common ACE Inhibitors Recommended for the Treatment of CHF
- Table 3-4: Common Angiotensin II Receptor Antagonists Recommended for the Treatment of CHF
- Table 3-5: Common Receptor Antagonists Recommended for the Treatment of CHF
- Table 3-6: Common Diuretics Recommended for the Treatment of CHF
- Table 3-7: Common Inotropic Drugs Available for the Treatment of CHF
- Table 3-8: Common Vasodilators Available for the Treatment of CHF
- Table 3-9: Common Aldosterone Blocking Drugs Recommended for the Treatment of CHF
- Table 3-10: New Drugs in Development for the Treatment of CHF
CHAPTER FOUR: CONGESTIVE HEART FAILURE PATIENT MANAGEMENT
- Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of Congestive Heart Failure by Stage of the Disease
- Table 4-1: ACC/AHA Staging of Congestive Heart Failure
- Table 4-2: 2005 ACC/AHA Guidelines for Evaluation and Therapy for Congestive Heart Failure
CHAPTER FIVE: THE MARKET FOR CHF PHARMACEUTICALS
- Table 5-1: Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017
- Figure 5-1: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017
- Figure 5-2: Distribution of the Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017
- Table 5-2: Estimated Market Potential for CHF Pharmaceuticals in the United States: 2007 - 2017 ($Billions)
- Figure 5-3: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the United States: 2007 - 2017
- Figure 5-4: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the United States: 2007 - 2017
- Table 5-3: Estimated Market Potential for CHF Pharmaceuticals in the Major European Markets: 2007 - 2017
- Figure 5-5: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Major European Markets: 2007 - 2017
- Figure 5-6: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the Major European Markets: 2007 - 2017
- Table 5-4: Estimated Market Potential for CHF Pharmaceuticals in the Japanese Market: 2007 - 2017
- Figure 5-7: Trending in the Estimated Market Potential for CHF Pharmaceuticals in the Japanese Market: 2007 - 2017
- Figure 5-8: Distribution of the Estimated Market Potential by Segments for CHF Pharmaceuticals in the Japanese Market: 2007 - 2017
